New human data hints at psychedelics' potential to combat inflammation
A new study suggests that psychedelics like psilocybin may reduce inflammation in humans, offering potential for treating diseases like Parkinson's. Researchers found lower inflammation levels in patients after psilocybin sessions, with some effects lasting a month. The findings build on earlier lab studies showing similar benefits in animals and cells.
Researchers found that psilocybin reduced inflammation in people with Parkinson's disease, based on blood tests showing lower levels of inflammation markers after treatment.
The results suggest psychedelics could have broader medical applications beyond mental health, potentially helping treat conditions linked to inflammation and immune issues.
The study shows how new research can uncover unexpected health benefits, offering hope for new treatments and encouraging further exploration of psychedelics in medicine.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.